Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Non-deal roadshow with Truist on 10/18

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Oct 11, 2022 10:20am

83 Views

Post# 35017063

RE:Non-deal roadshow with Truist on 10/18

This is great news! Thanks for sharing!

SPCEO1 wrote: Truist, a mid-range US bank with a small but growing brokerage operation, which helped arrange the debt financing THTX did this summer will be introducing THTX to clients on 10/18. Truist has not written a report yet on THTX but this would seem to indicate one is coming. This event is billed as a “non-deal roadshow”, which tells potential clients of Truist they are not pitching a stock offering as they introduce THTX to them. What can we take away from this news:

Whatever we hear this Thursday is likely to be good news as they will be looking to get out and talk about it to investors quickly.

Whatever they announce on Thursday will also likely not be huge positive news one might expect just prior to an actual share offering. So we expect good news that eventually leads to bigger news later when a share offering is launched. This likely will occur once market conditions improve as the bear market is squelching just about all share offerings right now.

There is a good chance Truist will write a research report on THTX, which will undoubtedly be positive in its tone.

Truist is not a top tier brokerage firm so THTX has not yet been able to get the attention of such firms (although we know there was some earlier interaction with JP Morgan).

So, this is yet another hint THTX is on a good path with TH-1902 and that it is actively seeking to leverage the few relationships it has with brokers to re-engage with investors. We should get some good news on Thursday as I cannot see THTX arranging this roadshow if they did not have some good news to share.